Resources for Researchers : Immunological Diseases : NIDDK

Resources for Researchers : Immunological Diseases

                        Immunological Diseases Databases, Registries and Information

                        back to top

                        Bioinformatics Information Support Contract (BISC)

                        http://www.niddk.nih.gov/fund/diabetesspecialfunds/consortia/BISC.pdf

                        The goal of the Bioinformatics Integration Support Contract (BISC) is to advance the discovery and testing of new therapies for immune-mediated diseases and to further the understanding of the basis of innate and adaptive immunity by providing advanced computer support for scientific data handling and disseminating best practices in scientific data analysis.

                        For more information, contact Dr. Lisa Spain, DEM, Director, Immunobiology of Type 1 Diabetes Program and Autoimmune Endocrine Diseases Program.

                        Central NIDDK Repository for Biosamples and Data

                        http://www.niddkrepository.org     EXIT Disclaimer

                        On July 1, 2003, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) established Central NIDDK Repositories for biosamples and data collected in clinical studies. The purpose of the Central Repositories is to expand the usefulness of these studies by providing access to the biosamples and data to a wider research community beyond the end of the study.

                        For more information, contact Dr. Rebekah Rasooly, Deputy Director of the Division of Kidney, Urologic, and Hematologic Diseases.

                        Collaborative Islet Transplant Registry (CITR)

                        http://www.citregistry.org     EXIT Disclaimer

                        The mission of CITR is to expedite progress and promote safety in islet/beta cell transplantation through the collection, analysis, and communication of comprehensive and current data on all islet/beta cell transplants performed in North America and soon some transplants in Europe and Australia. An Annual Report that is available on the public web site. This site serves as a repository for general information concerning protocols, clinical transplantation sites, publications, and other information of interest to the general community.

                        For more information, contact Dr. Michael Appel, DEM, Director, Islet Biology and Transplantation Research Program.

                        Diabetes Prevention Trial--Type 1 (DPT-1) dataset

                        https://www.niddkrepository.org/niddk/jsp/public/dataset.jsp#DPT-1       EXIT Disclaimer

                        The Diabetes Prevention Type 1 (DPT-1) trial is a NIDDK-funded multi-center clinical trial to determine if treatment with beta-cell antigens can delay the onset of Type 1 Diabetes Mellitus (Type 1 DM) in non-diabetic relatives of persons with Type 1 DM. Insulin is a well characterized antigen specifically produced by beta-cells, and it was used for this purpose in the initial DPT-1 studies. The protocol for high risk subjects uses daily subcutaneous insulin injections and an annual course of intravenous insulin treatment, while the protocol for intermediate risk subjects uses daily doses of insulin administered orally.

                        For more information, contact Dr. Catherine Cowie, DEM, Director, Diabetes Epidemiology Program.

                        Epidemiology of Diabetes Interventions and Complications (EDIC)

                        http://www.niddk.nih.gov/patient/edic/edic-public.htm

                        or http://www.bsc.gwu.edu/bsc/studies/edic.html     EXIT Disclaimer

                        An observational study examining the risk factors associated with the long-term complications of type 1 diabetes. The study began in 1994 and follows the 1441 participants previously enrolled in the Diabetes Control and Complications Trial (DCCT).

                        For more information, contact Dr. Catherine Cowie, DEM, Director, Diabetes Epidemiology Program.

                        Major Histocompatibility Complex Database (dbMHC)

                        http://www.ncbi.nlm.nih.gov/projects/mhc/MHC.fcgi?cmd=init

                        The dbMHC database provides an open, publicly accessible platform for DNA and clinical data related to the human Major Histocompatibility Complex (MHC).

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        National Gene Vector Laboratories (NGVL)

                        http://www.ngvl.org/     EXIT Disclaimer

                        The National Gene Vector Laboratories (NGVL) are composed of an interactive group of academic production and pharm/tox laboratories whose primary goal is to provide eligible investigators with clinical grade vectors for phase I/II gene therapy clinical trials and to provide support for relevant pharmacology/toxicology studies leading up to clinical gene transfer protocols. If the application is approved, clinical grade material will be produced at no cost to the investigator.

                        For more information, contact Dr. Catherine McKeon, DEM, Senior Advisor for Genetic Research in Diabetes, Endocrinology and Metabolic Diseases.

                        Immunological Diseases Multicenter Clinical Research

                        back to top

                        Autoimmunity Centers of Excellence (ACEs)


                        The objective of this initiative is to support integrated centers of basic, pre-clinical and clinical research in autoimmunity, emphasizing novel approaches and state-of-the-art technology to increase our understanding of the basic mechanisms of autoimmunity and self tolerance and to translate that information to the clinical setting.

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        Collaborative Islet Transplant Registry (CITR)

                        http://www.citregistry.org     EXIT Disclaimer

                        The mission of CITR is to expedite progress and promote safety in islet/beta cell transplantation through the collection, analysis, and communication of comprehensive and current data on all islet/beta cell transplants performed in North America and soon some transplants in Europe and Australia. An Annual Report that is available on the public web site. This site serves as a repository for general information concerning protocols, clinical transplantation sites, publications, and other information of interest to the general community.

                        For more information, contact Dr. Michael Appel, DEM, Director, Islet Biology and Transplantation Research Program.

                        Cooperative Study Group for Autoimmune Disease Prevention


                        The mission of these Prevention Centers is to engage in scientific discovery which significantly advances knowledge for the prevention and regulation of autoimmune disease.

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        Diabetes Prevention Trial--Type 1 (DPT-1)

                        http://www.niddk.nih.gov/patient/dpt_1/dpt_1.htm

                        The Diabetes Prevention Trial--Type 1 (DPT-1) consisted of two clinical trials that sought to delay or prevent type 1 diabetes, also known as insulin-dependent diabetes. These efforts are being continued by the Type 1 Diabetes TrialNet consortium EXIT Disclaimer. See also DPT-1 Dataset EXIT Disclaimer.

                        For more information, contact Dr. Catherine Cowie, DEM, Director, Diabetes Epidemiology Program.

                        Diabetes Prevention Trial--Type 1 (DPT-1) dataset

                        https://www.niddkrepository.org/niddk/jsp/public/dataset.jsp#DPT-1      EXIT Disclaimer

                        The Diabetes Prevention Type 1 (DPT-1) trial is a NIDDK-funded multi-center clinical trial to determine if treatment with beta-cell antigens can delay the onset of Type 1 Diabetes Mellitus (Type 1 DM) in non-diabetic relatives of persons with Type 1 DM. Insulin is a well characterized antigen specifically produced by beta-cells, and it was used for this purpose in the initial DPT-1 studies. The protocol for high risk subjects uses daily subcutaneous insulin injections and an annual course of intravenous insulin treatment, while the protocol for intermediate risk subjects uses daily doses of insulin administered orally.

                        For more information, contact Dr. Catherine Cowie, DEM, Director, Diabetes Epidemiology Program.

                        Diabetes Research in Children Network (DirecNet)

                        http://public.direc.net/     EXIT Disclaimer

                        The mission of DirecNet is to investigate the potential use of glucose monitoring technology and its impact on the management of type 1 diabetes in children.

                        For more information, contact Dr. Mary Horlick, DDN, Director, Pediatric Clinical Obesity Program.

                        Epidemiology of Diabetes Interventions and Complications (EDIC)

                        http://www.niddk.nih.gov/patient/edic/edic-public.htm

                        or http://www.bsc.gwu.edu/bsc/studies/edic.html     EXIT Disclaimer

                        An observational study examining the risk factors associated with the long-term complications of type 1 diabetes. The study began in 1994 and follows the 1441 participants previously enrolled in the Diabetes Control and Complications Trial (DCCT).

                        For more information, contact Dr. Catherine Cowie, DEM, Director, Diabetes Epidemiology Program.

                        Immune Tolerance Network (ITN)

                        http://www.immunetolerance.org     EXIT Disclaimer

                        The ITN is an international consortium of scientists and physicians dedicated to the clinical evaluation of novel tolerogenic approaches for the treatment of autoimmune diseases, asthma and allergic diseases, and the prevention of graft rejection.

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        Islet Transplantation Trials for Type 1 Diabetes

                        http://www.isletstudy.org/      EXIT Disclaimer

                        A network of centers will conduct studies of islet transplantation in patients with type 1 diabetes to improve the safety and long-term success of methods for transplanting islets.

                        For more information, contact Dr. Thomas Eggerman, DEM, Director, Islet Transplantation Clinical Trials Program.

                        SEARCH for Diabetes in Youth

                        http://www.searchfordiabetes.org/     EXIT Disclaimer

                        SEARCH is a multi-center study that identifies cases of diabetes in children/youth < 20 years of age in six geographically dispersed populations that encompass the ethnic diversity of the United States.

                        For more information, contact Dr. Barbara Linder, DEM, Senior Advisor for Childhood Diabetes Research.

                        The Environmental Determinant of Diabetes in the Young (TEDDY)

                        http://teddy.epi.usf.edu/     EXIT Disclaimer

                        This consortium is organizing international efforts to identify infectious agents, dietary factors, or other environmental factors that trigger type 1 diabetes in genetically susceptible people.

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        Trial to Reduce IDDM in the Genetically at Risk (TRIGR)

                        http://trigr.epi.usf.edu/     EXIT Disclaimer

                        The primary objective of this multi-center, international study is to determine whether weaning to a casein hydrolysate formula during the first 6-8 months of life in place of cow's milk based formula reduces the incidence of autoimmunity and type 1 diabetes in genetically susceptible newborn infants.

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        Type 1 Diabetes TrialNet

                        http://www.diabetestrialnet.org/     EXIT Disclaimer

                        This clinical network seeks to prevent type 1 diabetes in high-risk people and to preserve insulin production in those newly diagnosed.

                        For more information, contact Dr. Ellen Leschek, Type 1 Diabetes Trialnet Program Director.

                        Immunological Diseases Basic Research Networks

                        back to top

                        Animal Models of Diabetic Complications Consortium (AMDCC)

                        www.amdcc.org     EXIT Disclaimer

                        The AMDCC is an interdisciplinary consortium designed to develop animal models that closely mimic the human complications of diabetes for the purpose of studying disease pathogenesis, prevention and treatment. The consortium consists of thirteen “pathobiology sites” that study complications such as diabetic nephropathy, uropathy, neuropathy, cardiomyopathy and vascular disease. Additional goals of the AMDCC are to define standards to validate each diabetic complication for its similarity to the human disease, test the role of candidate genes that emerge from human genetic studies, and facilitate the exchange of animals, reagents, and expertise between members of the consortium and the greater scientific community. To ensure that all mice generated under the auspices of the AMDCC are phenotyped for a full duration of diabetes and across all relevant complications, the consortium has formed a close partnership with the NIDDK-funded Mouse Metabolic Phenotyping Centers (MMPCs). The MMPCs (www.mmpc.org) conduct detailed metabolic phenotyping of genetically altered mice and other mouse models that are useful for understanding diabetes and its complications, obesity, and related metabolic diseases or conditions.

                        For more information, contact Dr. Chris Ketchum, KUH, Director, Basic Renal Biology Program.

                        Central NIDDK Repository for Biosamples and Data

                        http://www.niddkrepository.org     EXIT Disclaimer

                        On July 1, 2003, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) established Central NIDDK Repositories for biosamples and data collected in clinical studies. The purpose of the Central Repositories is to expand the usefulness of these studies by providing access to the biosamples and data to a wider research community beyond the end of the study.

                        For more information, contact Dr. Rebekah Rasooly, Deputy Director of the Division of Kidney, Urologic, and Hematologic Diseases.

                        Cooperative Study Group for Autoimmune Disease Prevention


                        The mission of these Prevention Centers is to engage in scientific discovery which significantly advances knowledge for the prevention and regulation of autoimmune disease.

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        Immune Tolerance Network (ITN)

                        http://www.immunetolerance.org     EXIT Disclaimer

                        The ITN is an international consortium of scientists and physicians dedicated to the clinical evaluation of novel tolerogenic approaches for the treatment of autoimmune diseases, asthma and allergic diseases, and the prevention of graft rejection.

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        Islet Cell Resource Centers (ICR)

                        http://icr.coh.org/     EXIT Disclaimer

                        The three major goals of the ICRs are: 1) to provide pancreatic islets of cGMP-quality to eligible investigators for use in FDA approved, IRB-approved transplantation protocols; 2) to optimize the harvest, purification, function, storage, and shipment of islets while developing tests that characterize the quality and predict the effectiveness of islets transplanted into patients with diabetes mellitus; and 3) to provide pancreatic islets for basic science studies.

                        For more information, contact Dr. Michael Appel, DEM, Director, Islet Biology and Transplantation Research Program.

                        Non-human Primate Transplantation Tolerance Cooperative Study Group (NHPCSG)

                        http://www.niddk.nih.gov/fund/diabetesspecialfunds/consortia/NHP.pdf     EXIT Disclaimer

                        The NHPCSG, a multi-institution consortium, was established to evaluate the safety and efficacy of novel donor-specific, tolerance induction therapies in non-human primate (NHP) models of kidney and islet transplantation. The program also supports research into the immunological mechanisms of tolerance induction and development of surrogate markers for the induction, maintenance, and loss of tolerance.

                        For more information, contact Dr. Michael Appel, DEM, Director, Islet Biology and Transplantation Research Program.

                        Type 1 Diabetes Genetics Consortium (T1DGC)

                        http://www.t1dgc.org     EXIT Disclaimer

                        T1DGC was established with the primary goal of organizing international efforts to identify genes that determine an individual's risk of type 1 diabetes.

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        Immunological Diseases Reagents

                        back to top

                        Central NIDDK Repository for Biosamples and Data

                        http://www.niddkrepository.org     EXIT Disclaimer

                        On July 1, 2003, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) established Central NIDDK Repositories for biosamples and data collected in clinical studies. The purpose of the Central Repositories is to expand the usefulness of these studies by providing access to the biosamples and data to a wider research community beyond the end of the study.

                        For more information, contact Dr. Rebekah Rasooly, Deputy Director of the Division of Kidney, Urologic, and Hematologic Diseases.

                        National Gene Vector Laboratories (NGVL)

                        http://www.ngvl.org/     EXIT Disclaimer

                        The National Gene Vector Laboratories (NGVL) are composed of an interactive group of academic production and pharm/tox laboratories whose primary goal is to provide eligible investigators with clinical grade vectors for phase I/II gene therapy clinical trials and to provide support for relevant pharmacology/toxicology studies leading up to clinical gene transfer protocols. If the application is approved, clinical grade material will be produced at no cost to the investigator.

                        For more information, contact Dr. Catherine McKeon, DEM, Senior Advisor for Genetic Research in Diabetes, Endocrinology and Metabolic Diseases.

                        Immunological Diseases Services

                        back to top

                        Center for Inherited Disease Research (CIDR)

                        http://www.cidr.jhmi.edu     EXIT Disclaimer

                        A centralized facility established to provide genotyping and statistical genetics services for investigators seeking to identify genes that contribute to human disease. CIDR concentrates primarily on multifactorial hereditary disease although linage analysis of single gene disorders can also be accommodated.

                        For more information, contact Dr. Catherine McKeon, DEM, Senior Advisor for Genetic Research in Diabetes, Endocrinology and Metabolic Diseases.

                        Central NIDDK Repository for Biosamples and Data

                        http://www.niddkrepository.org     EXIT Disclaimer

                        On July 1, 2003, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) established Central NIDDK Repositories for biosamples and data collected in clinical studies. The purpose of the Central Repositories is to expand the usefulness of these studies by providing access to the biosamples and data to a wider research community beyond the end of the study.

                        For more information, contact Dr. Rebekah Rasooly, Deputy Director of the Division of Kidney, Urologic, and Hematologic Diseases.

                        Islet Cell Resource Centers (ICR)

                        http://icr.coh.org/     EXIT Disclaimer

                        The three major goals of the ICRs are: 1) to provide pancreatic islets of cGMP-quality to eligible investigators for use in FDA approved, IRB-approved transplantation protocols; 2) to optimize the harvest, purification, function, storage, and shipment of islets while developing tests that characterize the quality and predict the effectiveness of islets transplanted into patients with diabetes mellitus; and 3) to provide pancreatic islets for basic science studies.

                        For more information, contact Dr. Michael Appel, DEM, Director, Islet Biology and Transplantation Research Program.

                        Rapid Access to Intervention Development (NIH RAID)

                        http://nihroadmap.nih.gov/raid/     EXIT Disclaimer

                        NIH RAID provides a variety of contract services researchers need to bring promising potential therapeutics to trial.



                        Sequencing the NOD Mouse

                        http://www.niddk.nih.gov/fund/diabetesspecialfunds/consortia-networks/nod.htm

                        This project is a collaboration of four centers, working on a genome-wide basis, to generate a finished sequence of the non-obese diabetic (NOD) mouse genome, dovetailing with a number of targeted sequencing programs.

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        Type 1 Diabetes-Rapid Access to Intervention Development (T1D-RAID)

                        http://www.niddk.nih.gov/fund/diabetesspecialfunds/T1D-RAID/

                        The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials.

                        For more information, contact Dr. Myrlene Staten, DEM, Senior Advisor, Diabetes Research Translation Program.

                        Immunological Diseases Standardization Programs

                        back to top

                        Diabetes Autoantibody Standardization Program (DASP)

                        http://www.idsoc.org/committees/antibody/dasphome.html     EXIT Disclaimer

                        The fundamental aim of DASP is to improve the measurements of the autoantibodies predictive of type 1 diabetes.

                        For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

                        Immunological Diseases Tissues, Cells, Animals

                        back to top

                        Animal Models of Diabetic Complications Consortium (AMDCC)

                        www.amdcc.org     EXIT Disclaimer

                        The AMDCC is an interdisciplinary consortium designed to develop animal models that closely mimic the human complications of diabetes for the purpose of studying disease pathogenesis, prevention and treatment. The consortium consists of thirteen “pathobiology sites” that study complications such as diabetic nephropathy, uropathy, neuropathy, cardiomyopathy and vascular disease. Additional goals of the AMDCC are to define standards to validate each diabetic complication for its similarity to the human disease, test the role of candidate genes that emerge from human genetic studies, and facilitate the exchange of animals, reagents, and expertise between members of the consortium and the greater scientific community. To ensure that all mice generated under the auspices of the AMDCC are phenotyped for a full duration of diabetes and across all relevant complications, the consortium has formed a close partnership with the NIDDK-funded Mouse Metabolic Phenotyping Centers (MMPCs). The MMPCs (www.mmpc.org) conduct detailed metabolic phenotyping of genetically altered mice and other mouse models that are useful for understanding diabetes and its complications, obesity, and related metabolic diseases or conditions.

                        For more information, contact Dr. Chris Ketchum, KUH, Director, Basic Renal Biology Program.

                        Central NIDDK Repository for Biosamples and Data

                        http://www.niddkrepository.org     EXIT Disclaimer

                        On July 1, 2003, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) established Central NIDDK Repositories for biosamples and data collected in clinical studies. The purpose of the Central Repositories is to expand the usefulness of these studies by providing access to the biosamples and data to a wider research community beyond the end of the study.

                        For more information, contact Dr. Rebekah Rasooly, Deputy Director of the Division of Kidney, Urologic, and Hematologic Diseases.

                        Islet Cell Resource Centers (ICR)

                        http://icr.coh.org/     EXIT Disclaimer

                        The three major goals of the ICRs are: 1) to provide pancreatic islets of cGMP-quality to eligible investigators for use in FDA approved, IRB-approved transplantation protocols; 2) to optimize the harvest, purification, function, storage, and shipment of islets while developing tests that characterize the quality and predict the effectiveness of islets transplanted into patients with diabetes mellitus; and 3) to provide pancreatic islets for basic science studies.

                        For more information, contact Dr. Michael Appel, DEM, Director, Islet Biology and Transplantation Research Program.

                        Mutant Mouse Regional Resource Centers (MMRRC)

                        http://www.mmrrc.org/     EXIT Disclaimer

                        The goal of the MMRRC program is to enhance the availability of and help ensure the quality of genetically modified mice for biomedical research of human and animal biology and disease.

                        For more information, contact Dr. Kristin Abraham, DEM, Director, Cell Signaling and Diabetes Centers Program.

                        Non-human Primate Transplantation Tolerance Cooperative Study Group (NHPCSG)

                        http://www.niddk.nih.gov/fund/diabetesspecialfunds/consortia/NHP.pdf

                        The NHPCSG, a multi-institution consortium, was established to evaluate the safety and efficacy of novel donor-specific, tolerance induction therapies in non-human primate (NHP) models of kidney and islet transplantation. The program also supports research into the immunological mechanisms of tolerance induction and development of surrogate markers for the induction, maintenance, and loss of tolerance.

                        For more information, contact Dr. Michael Appel, DEM, Director, Islet Biology and Transplantation Research Program.

                        Type 1 Diabetes Mouse Repository at Jackson Laboratory (T1DR)

                        http://www.jax.org/t1dr/     EXIT Disclaimer

                        NIDDK has funded a Type 1 Diabetes Resource (T1DR) at The Jackson Laboratory (TJL). The purpose of this resource is to collect and cryopreserve ~150 mouse stocks important to research in type 1 diabetes.

                        For more information, contact Dr. Kristin Abraham, DEM, Director, Cell Signaling and Diabetes Centers Program.

                        Immunological Diseases Useful Tools

                        back to top

                        There are none at this time. Please check back.

                        Page last updated: January 05, 2009

                        General inquiries may be addressed to: Office of Communications & Public Liaison
                        NIDDK, NIH
                        Building 31. Rm 9A06
                        31 Center Drive, MSC 2560
                        Bethesda, MD 20892-2560
                        USA
                        For information about NIDDK programs: 301.496.3583

                        The National Institutes of Health   Department of Health and Human Services   USA.gov is the U.S. government's official web portal to all federal, state, and local government web resources and services.  HONcode Seal - Link to the Health on the Net Foundation